Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Two new triterpenoid saponins from Aralia elata var. glabrescens (Franch. & Sav.) Pojark. leaves.

Created on 06 Jul 2026

Authors

Xian Wang, Mengqi Yan, Bin Wang, Xiaotian Wu, Qiong Wu, Xinlan Li, Zhibin Wang, Meng Wang, Lihong Wu, Deqiang Yang, Mingzhuo Wei, Zhenyue Wang

Published in

Natural product research. Pages 1-10. Jul 05, 2026. Epub Jul 05, 2026.

Abstract

Two novel triterpenoids, named congmuyenoside F-G (1-2), and twelve known compounds (3-14), including three compounds (6, 7, 9) isolated from Aralia elata var. glabrescens (Franch. & Sav.) Pojark. for the first time, were identified from the total saponin fraction of Aralia elata leaves. Using AB-8 macroporous adsorption resin, reversed-phase ODS column chromatography, preparative HPLC and other separation techniques, triterpenoid saponins were obtained. The structures of two novel compounds were identified using extensive spectral data. In addition, the inhibitory effects of total saponin fraction and compounds 1-8 on the growth of 4T1, Hep G2, RKO, and H1299 tumour cell lines were tested by MTT assay, and the results showed that compounds 1 and 2 exhibited no inhibitory effect on the growth of the four tumour cell lines, whereas compound 5 exhibited inhibitory effects on all four cell lines with IC50 values of 23.69 ± 0.75, 68.00 ± 12.86, 27.96 ± 1.62, and 26.12 ± 1.67 μM, respectively.

PMID:
42402145
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement